NVE Schedules Conference Call on First Quarter Results
The quarterly call will be webcast live in a listen-only mode through the Investor Events page of NVE's Website ( www.nve.com). An archive of the call will also be available on NVE's Website.
To dial into the conference call, parties should call 855-552-4463 inside the United States, or 312-479-9427 and enter Meeting ID 7749 14 3539. Parties may request to ask questions on the call by dialing in or logging into https://chime.aws/7749143539.
NVE is a leader in the practical commercialization of spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store, and transmit information. The company manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data.
Statements we use that relate to future plans, events, financial results or performance are forward-looking statements that are subject to certain risks and uncertainties including, among others, the risk factors listed from time to time in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended March 31, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
4 minutes ago
- Winnipeg Free Press
S&P/TSX composite up Wednesday morning, U.S. markets also higher
TORONTO – Gains in battery metal stocks helped lift Canada's main stock index in late-morning trading on Wednesday, while U.S. markets also rose. The S&P/TSX composite index was up 76.52 points at 27,440.95. In New York, the Dow Jones industrial average was up 204.92 points at 44,707.36. The S&P 500 index was up 15.51 points at 6,325.13, while the Nasdaq composite was up 13.96 points at 20,906.65. The Canadian dollar traded for 73.45 cents US compared with 73.34 cents US on Tuesday. The September crude oil contract was down 44 cents US at US$64.87 per barrel. The August gold contract was down US$20.60 at US$3,423.10 an ounce. Monday Mornings The latest local business news and a lookahead to the coming week. This report by The Canadian Press was first published July 23, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD)
Globe and Mail
4 minutes ago
- Globe and Mail
SEGG Media (NASDAQ: SEGG, LTRYW) Taps IBN to Lead Corporate Communications
SEGG Media (NASDAQ: SEGG, LTRYW), a technology company focused on the convergence of sports, entertainment and gaming, has engaged IBN to lead its corporate communications. The move follows SEGG Media's rebrand and expansion across three verticals: Entertainment and With a $100 million financing facility and acquisitions in progress, SEGG Media is advancing a multi-vertical strategy to unify fan experiences across digital platforms. IBN will support the effort through its broad investor-focused media network and communications tools. To view the full press release, visit About SEGG Media Corporation SEGG Media is a global sports, entertainment and gaming group operating digital assets such as and Focused on immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications
Globe and Mail
4 minutes ago
- Globe and Mail
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
Thermo Fisher Scientific Inc. 's TMO second-quarter 2025 adjusted earnings per share (EPS) of $5.36 beat the Zacks Consensus Estimate by 2.7%. However, the figure decreased 0.2% year over year. The adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs. GAAP EPS was $4.28, up 6% on a year-over-year basis. Following the earnings announcement, shares of TMO rose 7.7% in pre-market trading today. TMO's Q2 Revenues in Detail Revenues in the quarter increased 2.9% year over year to $10.85 billion. Moreover, the top line surpassed the Zacks Consensus Estimate by 1.9%. Organic revenues in the reported quarter increased 2% year over year. Thermo Fisher's Segmental Analysis Thermo Fisher operates under four business segments, as discussed below: Life Sciences Solutions Revenues in the Life Sciences Solutions segment (23% of total revenues) increased 6.1% year over year to $2.50 billion. The number surpassed our model's estimate of $2.37 billion. Analytical Instruments Revenues in this segment (15.9%) declined 3% year over year to $1.73 billion. The figure missed our model's estimate of $1.84 billion. Specialty Diagnostics Revenues in the Specialty Diagnostics segment (10.4%) increased 1.5% year over year to $1.13 billion. The number missed our model's prediction of $1.15 billion. Laboratory Products and Biopharma Services Revenues in this segment (55.2%) rose 4.1% year over year to $5.99 billion. Our model's estimate was $5.71 billion. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) TMO's Margin Performance Gross margin of 41.2% in the second quarter contracted 83 basis points (bps) year over year due to a 4.4% increase in the cost of revenues. In the quarter, selling, general and administrative expenses rose 5.4% to $1.78 billion. Research and development expenses increased 3.8% to $352 million. The adjusted operating margin in the quarter was 21.6%, reflecting a contraction of 124 bps. Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise TMO's Financial Position The company ended the second quarter of 2025 with cash and cash equivalents and short-term investments of $6.39 billion compared with $5.95 billion at the end of the first quarter of 2025. Cumulative net cash from operating activities at the end of the second quarter was $2.12 billion compared with $3.21 billion a year ago. Thermo Fisher has a consistent dividend-paying history, with the five-year annualized dividend growth of 14.86%. Our Take on Thermo Fisher Stock Thermo Fisher exited the second quarter of 2025 with better-than-expected results, wherein both earnings and revenues beat the respective estimates. Barring the Analytical Instruments segment, all other business segments reported growth during the quarter. However, contraction of both margins in the quarter was discouraging. The company will provide its 2025 guidance on the earnings call today. During the second quarter, the company advanced in its growth strategy by launching a range of next-generation, high-impact, innovative instruments, including the Thermo Scientific Orbitrap Astral Zoom mass spectrometer, the Thermo Scientific Orbitrap™ Excedion Pro mass spectrometer and the Thermo Scientific Krios 5 Cryo-TEM. These instruments help researchers deepen the understanding of complex diseases, advance precision medicine and enable the development of new therapies. In addition, TMO expanded the DynaDrive single-use bioreactor portfolio for drug production to include a new first-of-its-kind bench-scale system, enabling meaningful workflow efficiencies and seamless scale-up from the bench to commercialization. All these developments translated into meaningful commercial wins for the company in the second quarter, which is encouraging. TMO's Zacks Rank & Key Picks Thermo Fisher currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Veeva Systems VEEV and Boston Scientific BSX. Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted first-quarter 2025 adjusted EPS of $1.81, which exceeded the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%. You can see the complete list of today's Zacks #1 Rank stocks here. ISRG has an estimated long-term earnings growth rate of 15.1% compared with the industry's 14.4%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%. Veeva Systems, currently carrying a Zacks Rank #2 (Buy), reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. VEEV has an estimated long-term earnings growth rate of 23.3% compared with the industry's 19.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 10%. Boston Scientific, carrying a Zacks Rank #2 at present, reported a first-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 0.1%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 20.9%. BSX has a long-term earnings growth rate of 13.2% compared with the industry's 13.9%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Boston Scientific Corporation (BSX): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report
